Journal of the Association of Nurses in AIDS Care
Volume 20, Issue 3 , Pages 176-183 , May 2009

Alcohol and Race/Ethnicity Elicit Different Changes in Lipid Profiles in HIV-Infected Individuals Receiving Highly Active Antiretroviral Therapy

References 

  1. Albu JB, Murphy L, Frager DH, Johnson JA, Pi-Sunyer FX. Visceral fat and race-dependent health risks in obese non-diabetic premenopausal women. Diabetes. 1997;46:456–462
  2. Bausserman LL, Tashima KT, DiSpigno M, Maceroni D, Carpenter CC. Racial differences in serum lipids in HIV+ women treated with protease inhibitor regimens. HIV Clinical Trials. 2004;5:399–405
  3. Bozkurt B. Cardiovascular toxicity with highly active antiretroviral therapy: Review of clinical studies. Cardiovascular Toxicology. 2004;4:243–260
  4. Calza R, Manfredi R, Chiodo F. Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients. Journal of Antimicrobial Chemotherapy. 2004;53:10–14
  5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm A, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51
  6. de Jong , H JI, de Goede J, Griep LMO, Geleijnse JM. Alcohol consumption and blood lipids in elderly coronary patients. Metabolism: Clinical and Experimental. 2008;57:1286–1292
  7. Després JP, Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, et al. Race, visceral adipose tissue, plasma lipids, and lipoprotein lipase activity in men and women: The Health, Risk Factors, Exercise Training, and Genetics (HERITAGE) Family Study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1932–1938
  8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association. 2001;285:2486–2497
  9. Fauvel J, Bonnet E, Ruidavets JB, Ferrieres JB, Toffoletti A, Massipet PA, et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS. 2001;15:2397–2406
  10. Foulkes AS, Whol DA, Franl I, Puleo E, Restine S, Megan L, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. PLoS Med. 2006;3:e52
  11. Freudenheim JL, Ram M, Nie J, Muti P, Trevisan M, Shields PG, et al. Lung cancer in humans is not associated with lifetime total alcohol consumption or with genetic variation in alcohol dehydrogenase 3 (ADH3). Journal of Nutrition. 2003;133:3619–3624
  12. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monfort d'A, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. New England Journal of Medicine. 2007;356:1723–1735
  13. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, Vega JM, Yang A, Alston BL, et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS Clinical Trials Group 5108 Study. Clinical Trial, Phase I. Multicenter Study. Journal of Acquired Immune Deficiency Syndromes. 2005;39:307–312
  14. Gkrania-Klotsas E, Klotsas A-E. HIV and HIV treatment: Effects on fats, glucose and lipids. British Medical Bulletin. 2007;84:49–68
  15. Lovejoy JC, de la Bretonne JA, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: Effects of race. Metabolism. 1996;45:1119–1124
  16. Míguez MJ, Shor-Posner G, Morales G, Rodriguez A, Burbano X. HIV treatment in drug abusers: Impact of alcohol use. Addiction Biology. 2003;8:33–37
  17. Miguez-Burbano MJ, Lewis JE, Moreno J, Fishman J. Cognitive performance and the thymus among HIV-infected subjects receiving HAART. Journal of Biologics: Targets and Therapy. 2008;2:321–327
  18. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871
  19. Montes ML, Pulido F, Barros C, Condes E, Rubio R, Cepeda C, et al. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: Frequency, characterization and risk factors. Journal of Antimicrobial Chemotherapy. 2005;55:800–804
  20. National Institute on Alcohol Abuse and Alcoholism (1995). The physician's guide to helping patients with alcohol problems. Washington, DC: National Institutes of Health. NIH publication 95-3769.
  21. Olshan AF, Weissler MC, Watson MA, Bell DA. Risk of head and neck cancer and the alcohol dehydrogenase 3 genotype. Carcinogenesis. 2001;22:57–61
  22. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2008). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Retrieved February 15, 2009, from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
  23. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G. A metabolic syndrome in whites and African-Americans: The Atherosclerosis Risk in Communities Baseline Study. Diabetes Care. 1996;19:414–418
  24. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS. 1998;12:F37

PII: S1055-3290(09)00037-5

doi: 10.1016/j.jana.2009.02.004

Journal of the Association of Nurses in AIDS Care
Volume 20, Issue 3 , Pages 176-183 , May 2009

Article Tools